Mounjaro® vs Zepbound®: Same Active Ingredient, Different FDA Approvals

Mounjaro® and Zepbound® are both manufactured by Eli Lilly. Both contain the same active ingredient: tirzepatide. Both are dosed identically — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly subcutaneous injections. Pharmacologically, they are equivalent.

The differences are regulatory and commercial: Mounjaro® is FDA-approved for type 2 diabetes. Zepbound® is FDA-approved for chronic weight management. Same molecule, different label, different packaging, and — most consequentially for patients — different insurance coverage pathways.

If your insurance covers one and not the other, the choice usually makes itself. If it covers neither, compounded tirzepatide becomes the practical option for most patients seeking the same active ingredient at a lower out-of-pocket cost.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 receptors (which reduce appetite, slow gastric emptying, and improve insulin response) AND GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism is why tirzepatide tends to produce greater average weight loss than semaglutide-only medications in clinical trials.

Eli Lilly developed tirzepatide and originally brought it to market for type 2 diabetes under the brand name Mounjaro® (FDA approval, 2022). Once the weight-loss benefit became clear in trials and the regulatory pathway for an obesity indication became viable, Lilly filed a separate FDA approval for the same molecule branded as Zepbound® (approved 2023) — this time specifically for chronic weight management in adults with obesity or overweight plus a weight-related condition.

Why bother creating two brand names for the same molecule? Because FDA approval is granted by indication, not by molecule. Insurance coverage decisions, marketing, packaging, and even dosing pens are organized around those indication-specific brands. Splitting the molecule into Mounjaro® for diabetes and Zepbound® for weight loss let Lilly target each insurance and patient population with appropriate messaging and supply chains.

Mounjaro® — FDA-approved indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Prescribed primarily by endocrinologists and primary care providers for diabetes management. Weight loss occurs as a secondary effect, but the FDA labeling is diabetes-focused.

Zepbound® — FDA-approved indication: chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.

Practically, the indication determines:

• Which insurance plans will cover the medication, and at what tier

• Whether a prior authorization is needed

• How the prescribing provider documents medical necessity

• Which pharmacy systems route the order

A patient with type 2 diabetes whose primary goal is glucose control will typically be prescribed Mounjaro® and may get insurance coverage relatively easily. A patient with obesity but without diabetes whose primary goal is weight loss will typically be prescribed Zepbound® — but insurance coverage for weight-loss-indicated GLP-1s has historically been more restrictive, and many plans require prior authorization, lifestyle-modification documentation, or specific BMI thresholds.

Both medications use the same dose-escalation schedule, in the same available strengths:

• Week 1–4: 2.5 mg weekly (starting/titration dose, not therapeutic)

• Week 5–8: 5 mg weekly

• Week 9–12: 7.5 mg weekly

• Week 13–16: 10 mg weekly

• Week 17–20: 12.5 mg weekly

• Week 21+: 15 mg weekly (maximum maintenance dose)

Each dose is a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. Both brand-name versions ship as pre-filled single-use auto-injector pens. Patients self-administer at home after brief instruction.

The slow escalation exists to minimize gastrointestinal side effects during dose ramp-up. Many patients stabilize at a lower dose (5–10 mg) if their weight loss is adequate and side effects make higher doses uncomfortable. The maximum dose isn't always the best dose — it's the dose the FDA approved as the upper bound for studies. Real-world dosing should be personalized based on response and tolerability.

Because Mounjaro® and Zepbound® are pharmacologically identical, their side effect profiles are also identical. The most common side effects, especially during dose escalation:

• Nausea (most common, typically mild-to-moderate, often improves over time)

• Vomiting

• Diarrhea or constipation

• Decreased appetite (this is the intended effect but can become uncomfortable)

• Fatigue during dose increases

• Injection-site reactions (mild redness, soreness)

Less common but documented:

• Hair loss (typically temporary, related to rapid weight loss rather than the medication itself)

• Gallbladder issues (rare but possible)

• Pancreatitis (rare; both products carry a warning)

Both products carry FDA black-box warnings about thyroid C-cell tumors based on rodent studies, though the risk in humans is not established. Patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not use either medication. Patients with active pancreatitis or who are pregnant or planning pregnancy are also not candidates.

This is where Mounjaro® and Zepbound® actually diverge for patients — not in the molecule, but in how the U.S. payer system treats each indication.

Mounjaro® (diabetes indication) — Generally easier insurance coverage because type 2 diabetes is treated as a covered chronic condition by most plans. Many commercial plans cover Mounjaro® with prior authorization confirming type 2 diabetes diagnosis. Medicare Part D coverage varies. List price without insurance is high; Lilly offers a savings card for eligible commercial-insured patients that can reduce out-of-pocket cost meaningfully.

Zepbound® (weight-loss indication) — Coverage is significantly more variable. Many commercial plans exclude anti-obesity medications entirely as a class. Medicare Part D does not cover Zepbound® for weight loss (statutory exclusion). Plans that do cover it often require documented BMI thresholds, prior authorization, sometimes prior lifestyle-modification programs, and ongoing documentation of response. Lilly's savings programs apply for some commercial patients.

The practical effect: two patients can receive the exact same drug and have wildly different out-of-pocket costs depending on which brand was prescribed and what their insurance covers. This is one of the main reasons compounded tirzepatide became a meaningful third option for many adults.

Throughout 2023 and 2024, the FDA listed tirzepatide on its drug shortage list, citing demand exceeding supply. During that period, compounding pharmacies were legally permitted to prepare compounded tirzepatide formulations under federal compounding rules that activate during declared shortages.

In late 2024, the FDA removed tirzepatide from the shortage list, signaling that Eli Lilly had built supply to meet demand. The regulatory landscape around compounded tirzepatide has been actively litigated since, with implications for ongoing availability of compounded versions through standard 503A and 503B compounding pharmacy pathways.

Brand-name Mounjaro® and Zepbound® are now generally available through standard pharmacy channels for patients with prescriptions and insurance coverage. Patients without coverage, or whose plans don't cover the weight-loss indication, often look to compounded tirzepatide as a more accessible option.

Compounded tirzepatide is prepared by licensed United States compounding pharmacies — both 503A (patient-specific) and, where applicable, 503B (outsourcing facilities). The active ingredient is the same: tirzepatide. The formulation, packaging, and regulatory pathway are different.

Key differences from brand-name Mounjaro® and Zepbound®:

• Compounded preparations are not FDA-approved finished products

• They are not generic equivalents of the brand-name medications

• They are prepared on a per-prescription or batch basis by licensed pharmacies

• Dosing and concentration may vary between compounding pharmacies

• Cost is typically lower than brand-name out-of-pocket, but is rarely covered by insurance

Peak Medical Wellness prescribes compounded tirzepatide through licensed U.S. compounding pharmacies when clinically appropriate. We do not prescribe brand-name Mounjaro® or Zepbound®. Each prescription is provider-directed, with individualized dosing based on labs, response, and goals — and ongoing monitoring across treatment.

Compounded tirzepatide is not the right choice for everyone. Patients whose insurance covers brand-name Zepbound® or Mounjaro® and who prefer a finished, FDA-approved product should pursue that route with their provider. Patients without coverage, or who prefer the cost and accessibility profile of compounded options, may find the compounded route a reasonable fit after a real provider conversation.

The decision tree most patients actually face:

• If you have type 2 diabetes and good prescription coverage: brand-name Mounjaro® is the most direct path — talk to your endocrinologist or primary care provider.

• If you have a weight-loss-indication-covered insurance plan and meet the criteria: brand-name Zepbound® is a clean fit — talk to a weight-loss-experienced provider.

• If your insurance excludes weight-loss medications, or you'd be paying out-of-pocket either way: compounded tirzepatide is often a more accessible option — talk to a clinic experienced in prescribing it, like Peak Medical Wellness.

What you shouldn't do: choose between Mounjaro® and Zepbound® based on which one you think will work better. Pharmacologically they are the same medication. Choose based on your indication (diabetes vs weight loss), what your insurance covers, and your provider's clinical judgment.

Any path should involve a real provider relationship — baseline labs, dose titration, monitoring, and follow-up. GLP-1 medications work; what makes them work well over time is supervision, dose adjustment, and the lifestyle work that runs alongside the pharmacology.